Kyverna Therapeutics (KYTX) Enterprise Value (2023 - 2026)
Kyverna Therapeutics' (KYTX) quarterly Enterprise Value came in at -$233.0 million in Q1 2026, up 3.98% YoY from -$224.1 million in Q1 2025, and up 16.56% on a QoQ basis from -$279.3 million in Q4 2025.
Kyverna Therapeutics (KYTX) Enterprise Value (2023 - 2026) Analysis & Trends
Kyverna Therapeutics (KYTX) has 4 years of Enterprise Value data on file, last reported at -$233.0 million in Q1 2026.
- Quarterly Enterprise Value rose 3.98% year-over-year to -$233.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$233.0 million (up 3.98% YoY) and the FY2025 annual result came in at -$279.3 million, up 2.35% from the prior year.
- Enterprise Value advanced to -$233.0 million in Q1 2026, from -$279.3 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$23.0 million in Q3 2023 to a low of -$369.8 million in Q1 2024.
- A 4-year average of -$202.6 million and a median of -$233.0 million in 2026 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2024 — Enterprise Value sank 1300.11% — and 2025, when it surged 46.78%.
- Tracing KYTX's Enterprise Value over 4 years: stood at -$57.5 million in 2023, then plunged by 396.98% to -$286.0 million in 2024, then rose by 2.35% to -$279.3 million in 2025, then increased by 16.56% to -$233.0 million in 2026.
- The last three Enterprise Value figures came in at -$233.0 million (Q1 2026), -$279.3 million (Q4 2025), and -$171.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Kyverna Therapeutics | 505.26 Mn | 505.26 Mn | - | -199.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -199.43 Mn |
| Mar 31, 2026 | -233.00 Mn |
| Dec 31, 2025 | -279.25 Mn |
| Sep 30, 2025 | -171.14 Mn |
| Jun 30, 2025 | -210.30 Mn |
| Mar 31, 2025 | -242.65 Mn |
| Dec 31, 2024 | -285.98 Mn |
| Sep 30, 2024 | -321.56 Mn |
| Jun 30, 2024 | -346.24 Mn |
| Mar 31, 2024 | -369.79 Mn |
| Dec 31, 2023 | -57.54 Mn |
| Sep 30, 2023 | -22.97 Mn |
| Jun 30, 2023 | -53.43 Mn |
| Mar 31, 2023 | -39.79 Mn |